A detailed history of Susquehanna International Group, LLP transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 16,308 shares of TNGX stock, worth $49,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,308
Previous 14,830 9.97%
Holding current value
$49,576
Previous $127,000 1.57%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $11.93 $10,878 - $17,632
1,478 Added 9.97%
16,308 $125,000
Q2 2024

Aug 15, 2024

SELL
$6.66 - $10.15 $186,892 - $284,829
-28,062 Reduced 65.42%
14,830 $127,000
Q1 2024

May 07, 2024

BUY
$7.51 - $12.88 $123,734 - $212,210
16,476 Added 62.37%
42,892 $340,000
Q4 2023

Feb 14, 2024

BUY
$6.52 - $12.01 $10,288 - $18,951
1,578 Added 6.35%
26,416 $261,000
Q3 2023

Nov 14, 2023

BUY
$2.93 - $11.26 $26,926 - $103,479
9,190 Added 58.73%
24,838 $279,000
Q2 2023

Aug 11, 2023

SELL
$2.67 - $4.7 $33,230 - $58,496
-12,446 Reduced 44.3%
15,648 $51,000
Q1 2023

May 16, 2023

BUY
$3.76 - $8.06 $105,633 - $226,437
28,094 New
28,094 $110,000
Q3 2022

Nov 14, 2022

BUY
$3.25 - $5.46 $43,810 - $73,600
13,480 New
13,480 $49,000
Q2 2022

Aug 15, 2022

SELL
$3.86 - $8.01 $1.28 Million - $2.66 Million
-332,000 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$7.01 - $10.94 $1.51 Million - $2.35 Million
215,120 Added 184.05%
332,000 $2.52 Million
Q4 2021

Feb 14, 2022

BUY
$9.55 - $14.29 $1.12 Million - $1.67 Million
116,880 New
116,880 $1.28 Million

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $268M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.